tirzepatide for cardiovascular disease outcomes of semaglutide and patients with type 2 diabetes in clinical practice In patients with type 2

The estimated treatment difference for tirzepatide versus insulin degludec ranged from -0.59% to -1.04%, with all tirzepatide doses demonstrating statistical significance

Gastrointestinal symptoms such as nausea, which are among the most common side effects, generally improve within weeks after the final dose, though individual experiences vary

Backed by real science

The initial rapid and short-lived release facilitated by Large Dense Core Vesicles (LDCVs) at the plasma membrane is followed by a sustained release of insulin that depends on the mobilization of insulin-secreting granules (ISGs) to the plasma membrane for exocytosis 1

Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study